Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MiNA Therapeutics Ltd.

minatx.com

Latest From MiNA Therapeutics Ltd.

Deal Watch, M&A: Warp Drive And Its Partnerships Acquired By Revolution

Once expected to be absorbed by Sanofi, US biotech Warp Drive Bio now will become part of California’s Revolution Medicines in a stock transaction. Sosei elects against its option to acquire MiNA Therapeutics; MeiraGTX follows its June IPO with takeout of Vector Neurosciences. Other recent mergers and acquisitions... 

M & A Deals

BI’s Business Development Focus Remains On Early Collaboration

Boehringer Ingelheim’s US business development head Ioannis Sapountzis outlines BI’s efforts to catch up with competitors in NASH and immuno-oncology via early-stage partnerships and licensing deals.

Business Strategies Research and Development Strategies

Boehringer Ingelheim Confident Of A Happier Ending In NASH Than HCV

With a Phase II AOC3 inhibitor and a pair of preclinical partnerships with RNAi companies, the German pharma is taking its time to investigate a variety of approaches to the multi-factorial disease.

Research & Development Liver & Hepatic

Deal Watch: Boehringer's Busy End Of Year Includes Deals With Roche, Autifony

The German pharma options potassium channel modulator technology from Autifony and partners with Roche on immunological approaches to irritable bowel syndrome. Roche unveils discovery pacts with Confo and DiCE.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Hepatic (Liver)
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • MiNA Therapeutics Ltd.
  • Senior Management
  • Robert Habib, CEO
    David Blakey, PhD, CSO
  • Contact Info
  • MiNA Therapeutics Ltd.
    96 Kensington High St.
    London, W8 4SG
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register